RECENT POSTS


Beovu: What’s the latest with the ophthalmic community’s concerns?

Post by Admin, July 1, 2020.

Reports and opinions keep pouring in about Novartis’ Beovu® (brolucizumab), meant to treat wet or neovascular age-related macular degeneration (nAMD). In February, the American Society of Retina Sp...

Read More  
blog img